Leerink cuts Abbott Labs stock price target on mixed results By Investing.com

Abbott Laboratories’ Q1 results were mixed to slightly weak: worldwide sales rose 1% versus consensus and adjusted EPS matched expectations, but organic revenue missed and key areas including respiratory, diabetes, and Structural Heart underperformed. Leerink cut its price target to $106 from $119 and several other firms also reduced targets, citing lowered organic growth guidance and segment-specific weakness. Abbott now expects comparable growth of 6.5% to 7.5% including Exact Sciences, with second-half acceleration expected from new product launches.

Analysis

ABT’s reset looks less like a one-off miss and more like a credibility tax on near-term organic growth, which matters because this is a premium multiple stock that has historically been defended by consistency. The key second-order issue is not the small earnings miss; it’s that weaker diabetes, structural heart, and respiratory momentum all point to a broader deceleration in the highest-expectation parts of the portfolio, reducing the market’s willingness to underwrite second-half acceleration without clean proof points.

The downside risk is that guidance math gets harder if the new launches slip even modestly. In medtech, launch slippage tends to show up first in channel stocking and then in incremental gross margin pressure, so the next 1-2 quarters are likely to be judged on whether sequential growth re-accelerates rather than on absolute EPS. If that re-acceleration fails to materialize by the next print, the stock can keep grinding lower even without further estimate cuts, because buy-side models will de-rate the durability of the growth algorithm.

EXAS is the cleaner expression of the disappointment: if the acquisition contribution is coming in below prior expectations, the market may start to question whether the synergy and cross-sell assumptions embedded in broader diagnostics expectations are too aggressive. That could create spillover pressure on other diagnostics and diabetes-exposed suppliers, but the more interesting effect is competitive: peers with cleaner continuous glucose monitoring or faster electrophysiology launch cadence may gain share simply by being the “less messy” growth story.

The contrarian view is that this may be mostly a valuation reset rather than a fundamental break. With the stock near lows and sentiment already cautious, any evidence of stable ex-Exact Sciences base growth or better-than-feared second-half launch traction could force a sharp squeeze higher, especially if management can show orders and procedure volumes improving before reported revenue. The setup is therefore asymmetric: slow bleed downside if guidance credibility erodes further, but a meaningful reflexive bounce if the next data point restores confidence in the back-half ramp.

Key Decisions for Investors

• Short ABT vs long IHI or XLV on a 1-3 month horizon: use ABT as the cleaner idiosyncratic laggard if you want to express medtech execution risk without taking broad healthcare beta. Risk/reward improves if the stock loses the low-$90s support; cover on any confirmation of second-half acceleration.
• Buy ABT puts or put spreads into the next earnings cycle: favor 1-2 quarter-dated downside structures to monetize the market’s skepticism around launch timing and organic growth credibility. Use defined risk because implied volatility may remain elevated after the guide-down.
• Avoid long exposure to EXAS until management proves the revenue underperformance is transitory: the better trade is to wait for evidence of stabilization before stepping in, since the market may still be over-discounting acquisition-related synergies. If you want exposure, use a small starter long only after sequential growth inflects.
• Pair trade: long a cleaner procedural-growth medtech name versus short ABT for 2-4 months. The trade benefits from investors rotating toward names with less dependence on near-term product launches and fewer moving parts in guidance.
• Set a tactical buy level only if ABT reclaims prior support on volume after the next print: if fundamentals stabilize, the stock could mean-revert sharply from depressed levels, but catching the falling knife here is premature absent proof of sequential improvement.